请使用支持JavaScript的浏览器!
主营:医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
℡ 4000-520-616
℡ 4000-520-616
BD Biosciences/FMC7 FITC/CD23 PE/CD19 PerCP-Cy™5.5/331359
产品编号:331359
市  场 价:¥0.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: BD Biosciences
公      司:BD Biosciences,Inc.
公司分类:
BD Biosciences/FMC7 FITC/CD23 PE/CD19 PerCP-Cy™5.5/331359
商品介绍
Product DetailsRecommended AssayReferences

Description

BD Oncomark™ FMC7 FITC/CD23 PE/CD19 PerCP-Cy5.5 is intended for in vitro flow cytometric immunophenotyping of normal and abnormal subsets of B lymphocytes. The reagents detect expression of the FMC7 and CD23 antigens on normal and abnormal B cells. The FMC7 antigen is present in a subset of normal B lymphocytes, but is weak or undetectable in chronic lymphocytic leukemia (CLL). The CD23 antigen is not usually present in mantle cell lymphoma but might be present in other B-cell neoplasms such as B-cell CLL and small lymphocytic lymphomas. FMC7/CD23/CD19 assays are used in the diagnosis of hematologic disorders.

Contents

SpecificityCloneFormatIsotypeEntrez Gene ID
FMC7FMC7FITCIgM, κ931
CD23EBVCS-5 (also known as EBVCS 5)PEIgG1, κ2208
CD19SJ25C1 (also known as SJ25-C1)PerCP-Cy™5.5IgG1, κ930
Preparation and Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

  1. Protection of Laboratory Workers from Occupationally Acquired Infections–Second Edition; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 2001. NCCLS document M29-A2.

  2. Bloem AC, Chand MA, Dollekamp I, Rijkers GT. Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7. J Immunol. 1988;140:768-773.

  3. Brooks DA, Beckman IGR, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol. 1981;126:1373-1377.

  4. Capron M, Jouault T, Prin L, et al. Functional study of a monoclonal antibody to IgE Fc receptor (FcεR2) of eosinophils, platelets, and macrophages. J Exp Med. 1986;164:72-89.

  5. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.

  6. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol. 1998;25:6-10.

  7. Geisler CH, Larsen JK, E HN, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991;78:1795-1802.

  8. Gordon J, Rowe M, Walker L, Guy G. Ligation of the CD23,p45 (Blast-2, EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. Eur J Immunol. 1986;16:1075-1080.

  9. Gordon J, Webb A, Walker L, Guy G, Rowe M. Evidence of an association between CD23 and the receptor for a low molecular weight B-cell growth factor. Eur J Immunol. 1986;16:1627.

  10. Hassan IB, Hagberg H, Sundström C. Immunophenotype of hairy-cell leukemia. Eur J Haematol. 1990;45:172-176.

  11. Hoffkes HG, Schmidtke G, Uppenkamp M, Schmucker U. Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry. Clin Diagn Lab Immunol. 1996;3:30-36.

  12. Huh YO, Pugh WC, Kanjarjian HM, et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol. 1994;101:283-289.

  13. Hübl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry. 1998;34:71-74.

  14. Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.

  15. Kikutani H, Inui S, Sato R, et al. Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell. 1986;47:657-665.

  16. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol. 1996;105:451-457.

  17. Kintner C, Sugden B. Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr Virus. Nature. 1981;294:458-460.

  18. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B-lymphocyte development. Blood. 1987;70:1316-1324.

  19. Marti GE, Zenger V, Caproaso NE, et al. Antigenic expression of B-cell chronic lymphocytic leukemic lymphocytes. Anal Quant Cytol Histol. 1989;11:315-323.

  20. Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14:57-61.

  21. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640-1645.

  22. Moldenhauer G, Dörken B, Schwartz R, Pezzutto A, Knops J, Hammerling GJ. Analysis of ten B lymphocyte-specific workshop monoclonal antibodies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. New York, NY: Springer-Verlag; 1986;2:61-67.

  23. Nadler LM. B Cell/Leukemia Panel Workshop: summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. 1986;2:3-43.

  24. Nadler LM. Cluster report: CD23. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. 1986;2:25-26.

  25. Reichert T, DeBruyère M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopath. 1991;60:190-208.

  26. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-895.

  27. Stelzer GT, Marti G, Hurley A, McCoy P, Jr., Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30:214-230.

  28. Tedder T, Zhou L-J, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994;15:437-442.

  29. Thorley-Lawson D, Nadler L, Bhan A, Schooley R. Blast-2 (EBVCS), an early cell surface marker of human B cell activation, is superinduced by Epstein Barr Virus. J Immunol. 1985;134:3007-3012.

  30. Tworek JA, Singleton TP, Schnitzer B, Hsi ED, Ross CW. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol. 1998;110:582-589.

  31. Yukawa K, Kikutani H, Owaki H, et al. A B-cell– specific differentiation antigen, CD23, is a receptor for IgE (FcεR) on lymphocytes. J Immunol. 1987;138:2576-2580.

  32. Zola H, Neoh SH, Potter A, Melo JV, De Oliveria MSP, Catovsky D. Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules. Disease Markers. 1987;5:227-235.

品牌介绍

BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗,提高传染性疾病诊断的质量和速度,推进新型药物和疫苗的研究与发现。公司于1897年在纽约成立,总部位于美国新泽西州的富兰克林湖,业务可分为BD医疗、BD诊断、BD生物科学三大类,生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。

自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔